Greenwich LifeSciences, Inc.
GLSIHealthcare|Biotechnology|US
$15.17
+0.52 (+3.55%)
DCF Value
$0.13
Tangible Book / Share
$0.21
Cash / Share
$0.61
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05232916 Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Breast Cancer | P3 | Recruiting | 2,250 | RCT, Double-blind | Placebo, GLSI-100 |